Skip to main content
NASDAQ:KOD

Kodiak Sciences Competitors

$79.42
-2.28 (-2.79 %)
(As of 05/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$79.05
$84.53
50-Day Range
$81.70
$126.54
52-Week Range
$42.97
$171.21
Volume560,161 shs
Average Volume331,758 shs
Market Capitalization$4.07 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.42

Competitors

Kodiak Sciences (NASDAQ:KOD) Vs. TECH, ARGX, QGEN, NVAX, RGEN, and NBIX

Should you be buying KOD stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Kodiak Sciences, including Bio-Techne (TECH), argenx (ARGX), QIAGEN (QGEN), Novavax (NVAX), Repligen (RGEN), and Neurocrine Biosciences (NBIX).

Kodiak Sciences (NASDAQ:KOD) and Bio-Techne (NASDAQ:TECH) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Kodiak Sciences and Bio-Techne, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kodiak Sciences16602.38
Bio-Techne03702.70

Kodiak Sciences presently has a consensus price target of $128.0769, suggesting a potential upside of 61.27%. Bio-Techne has a consensus price target of $396.1111, suggesting a potential downside of 3.12%. Given Kodiak Sciences' higher possible upside, analysts clearly believe Kodiak Sciences is more favorable than Bio-Techne.

Profitability

This table compares Kodiak Sciences and Bio-Techne's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kodiak SciencesN/A-32.32%-23.86%
Bio-Techne32.69%12.20%8.09%

Valuation & Earnings

This table compares Kodiak Sciences and Bio-Techne's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kodiak SciencesN/AN/A$-47,370,000.00($1.25)-63.54
Bio-Techne$738.69 million21.53$229.30 million$3.86105.93

Bio-Techne has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

82.3% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 93.8% of Bio-Techne shares are owned by institutional investors. 39.3% of Kodiak Sciences shares are owned by company insiders. Comparatively, 3.8% of Bio-Techne shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Kodiak Sciences has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500. Comparatively, Bio-Techne has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500.

Summary

Bio-Techne beats Kodiak Sciences on 10 of the 13 factors compared between the two stocks.

Kodiak Sciences (NASDAQ:KOD) and argenx (NASDAQ:ARGX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Kodiak Sciences and argenx, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kodiak Sciences16602.38
argenx071102.61

Kodiak Sciences presently has a consensus price target of $128.0769, suggesting a potential upside of 61.27%. argenx has a consensus price target of $297.8750, suggesting a potential upside of 15.36%. Given Kodiak Sciences' higher possible upside, analysts clearly believe Kodiak Sciences is more favorable than argenx.

Profitability

This table compares Kodiak Sciences and argenx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kodiak SciencesN/A-32.32%-23.86%
argenxN/AN/AN/A

Valuation & Earnings

This table compares Kodiak Sciences and argenx's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kodiak SciencesN/AN/A$-47,370,000.00($1.25)-63.54
argenx$78.17 million169.47$-182,520,000.00($4.73)-54.59

Kodiak Sciences has higher earnings, but lower revenue than argenx. Kodiak Sciences is trading at a lower price-to-earnings ratio than argenx, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

82.3% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 54.2% of argenx shares are owned by institutional investors. 39.3% of Kodiak Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Kodiak Sciences has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500. Comparatively, argenx has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.

Summary

Kodiak Sciences beats argenx on 7 of the 12 factors compared between the two stocks.

Kodiak Sciences (NASDAQ:KOD) and QIAGEN (NYSE:QGEN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Kodiak Sciences and QIAGEN, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kodiak Sciences16602.38
QIAGEN05902.64

Kodiak Sciences presently has a consensus price target of $128.0769, suggesting a potential upside of 61.27%. QIAGEN has a consensus price target of $60.76, suggesting a potential upside of 31.29%. Given Kodiak Sciences' higher possible upside, analysts clearly believe Kodiak Sciences is more favorable than QIAGEN.

Profitability

This table compares Kodiak Sciences and QIAGEN's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kodiak SciencesN/A-32.32%-23.86%
QIAGEN11.18%17.51%8.44%

Valuation & Earnings

This table compares Kodiak Sciences and QIAGEN's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kodiak SciencesN/AN/A$-47,370,000.00($1.25)-63.54
QIAGEN$1.53 billion6.91$-41,460,000.00$1.4332.36

QIAGEN has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than QIAGEN, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

82.3% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 43.6% of QIAGEN shares are owned by institutional investors. 39.3% of Kodiak Sciences shares are owned by company insiders. Comparatively, 9.0% of QIAGEN shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Kodiak Sciences has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500. Comparatively, QIAGEN has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500.

Summary

QIAGEN beats Kodiak Sciences on 9 of the 13 factors compared between the two stocks.

Kodiak Sciences (NASDAQ:KOD) and Novavax (NASDAQ:NVAX) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Profitability

This table compares Kodiak Sciences and Novavax's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kodiak SciencesN/A-32.32%-23.86%
Novavax-133.10%-1,346.17%-45.85%

Valuation & Earnings

This table compares Kodiak Sciences and Novavax's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kodiak SciencesN/AN/A$-47,370,000.00($1.25)-63.54
Novavax$18.66 million507.52$-132,690,000.00($5.80)-22.04

Kodiak Sciences has higher earnings, but lower revenue than Novavax. Kodiak Sciences is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Kodiak Sciences and Novavax, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kodiak Sciences16602.38
Novavax11502.57

Kodiak Sciences presently has a consensus price target of $128.0769, suggesting a potential upside of 61.27%. Novavax has a consensus price target of $190.9286, suggesting a potential upside of 49.37%. Given Kodiak Sciences' higher possible upside, analysts clearly believe Kodiak Sciences is more favorable than Novavax.

Institutional & Insider Ownership

82.3% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 49.9% of Novavax shares are owned by institutional investors. 39.3% of Kodiak Sciences shares are owned by company insiders. Comparatively, 3.3% of Novavax shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Kodiak Sciences has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500. Comparatively, Novavax has a beta of 2.01, indicating that its stock price is 101% more volatile than the S&P 500.

Summary

Kodiak Sciences beats Novavax on 9 of the 13 factors compared between the two stocks.

Kodiak Sciences (NASDAQ:KOD) and Repligen (NASDAQ:RGEN) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

Institutional and Insider Ownership

82.3% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 84.3% of Repligen shares are owned by institutional investors. 39.3% of Kodiak Sciences shares are owned by company insiders. Comparatively, 1.7% of Repligen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Kodiak Sciences and Repligen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kodiak SciencesN/A-32.32%-23.86%
Repligen13.40%6.58%5.00%

Analyst Ratings

This is a breakdown of current ratings and target prices for Kodiak Sciences and Repligen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kodiak Sciences16602.38
Repligen00503.00

Kodiak Sciences currently has a consensus price target of $128.0769, suggesting a potential upside of 61.27%. Repligen has a consensus price target of $222.75, suggesting a potential upside of 29.81%. Given Kodiak Sciences' higher possible upside, equities analysts clearly believe Kodiak Sciences is more favorable than Repligen.

Risk and Volatility

Kodiak Sciences has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500. Comparatively, Repligen has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500.

Earnings and Valuation

This table compares Kodiak Sciences and Repligen's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kodiak SciencesN/AN/A$-47,370,000.00($1.25)-63.54
Repligen$270.24 million34.86$21.41 million$1.07160.37

Repligen has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Summary

Repligen beats Kodiak Sciences on 9 of the 13 factors compared between the two stocks.

Neurocrine Biosciences (NASDAQ:NBIX) and Kodiak Sciences (NASDAQ:KOD) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Institutional and Insider Ownership

95.3% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 82.3% of Kodiak Sciences shares are held by institutional investors. 4.3% of Neurocrine Biosciences shares are held by company insiders. Comparatively, 39.3% of Kodiak Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk & Volatility

Neurocrine Biosciences has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, Kodiak Sciences has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500.

Profitability

This table compares Neurocrine Biosciences and Kodiak Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neurocrine Biosciences8.96%18.18%9.50%
Kodiak SciencesN/A-32.32%-23.86%

Earnings & Valuation

This table compares Neurocrine Biosciences and Kodiak Sciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neurocrine Biosciences$788.10 million11.05$37.01 million$0.39236.28
Kodiak SciencesN/AN/A$-47,370,000.00($1.25)-63.54

Neurocrine Biosciences has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Neurocrine Biosciences and Kodiak Sciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neurocrine Biosciences071302.65
Kodiak Sciences16602.38

Neurocrine Biosciences currently has a consensus price target of $127.8333, indicating a potential upside of 38.72%. Kodiak Sciences has a consensus price target of $128.0769, indicating a potential upside of 61.27%. Given Kodiak Sciences' higher probable upside, analysts plainly believe Kodiak Sciences is more favorable than Neurocrine Biosciences.

Summary

Neurocrine Biosciences beats Kodiak Sciences on 10 of the 13 factors compared between the two stocks.

Ad Investing Trends
Shark Tank Investor: THIS is My Secret to Getting Rich
Shark Tank angel investor, Kevin O'Leary, has a word of advice for individual investors: "Always look for solutions… with the potential to solve vast problems." And today, the renowned investor believes he might have found just one of these solutions.

Kodiak Sciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Bio-Techne logo
TECH
Bio-Techne
1.8$408.88-1.6%$15.90 billion$738.69 million65.42Earnings Announcement
Dividend Announcement
argenx logo
ARGX
argenx
1.3$258.21-0.4%$13.25 billion$78.17 million-54.59Upcoming Earnings
Analyst Upgrade
Gap Down
QIAGEN logo
QGEN
QIAGEN
1.7$46.28-0.2%$10.55 billion$1.53 billion57.14
Novavax logo
NVAX
Novavax
1.8$127.82-8.1%$9.47 billion$18.66 million-24.49Earnings Announcement
Analyst Report
Gap Down
Repligen logo
RGEN
Repligen
1.9$171.60-2.2%$9.42 billion$270.24 million209.27Analyst Report
Analyst Revision
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$92.15-0.8%$8.71 billion$788.10 million99.09Analyst Report
CRISPR Therapeutics logo
CRSP
CRISPR Therapeutics
1.7$100.84-2.7%$7.64 billion$289.59 million-30.93Gap Down
Acceleron Pharma logo
XLRN
Acceleron Pharma
1.6$121.17-0.7%$7.35 billion$73.99 million-46.78Earnings Announcement
News Coverage
Fate Therapeutics logo
FATE
Fate Therapeutics
1.8$72.29-7.9%$6.80 billion$10.68 million-39.29Earnings Announcement
Analyst Revision
Gap Down
Denali Therapeutics logo
DNLI
Denali Therapeutics
1.5$51.17-6.5%$6.20 billion$26.68 million-23.15
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$42.48-0.5%$6.09 billion$195.99 million265.50Earnings Announcement
Analyst Downgrade
Insider Selling
Analyst Revision
News Coverage
Vir Biotechnology logo
VIR
Vir Biotechnology
1.4$39.11-1.6%$5.09 billion$8.09 million-16.57Earnings Announcement
China Biologic Products logo
CBPO
China Biologic Products
0.8$119.99-1.7%$4.72 billion$503.70 million33.52Upcoming Earnings
Adaptive Biotechnologies logo
ADPT
Adaptive Biotechnologies
1.6$32.91-0.7%$4.62 billion$85.07 million-34.64Analyst Upgrade
Gap Down
Twist Bioscience logo
TWST
Twist Bioscience
1.6$91.08-9.4%$4.45 billion$90.10 million-24.29Earnings Announcement
Gap Down
Beam Therapeutics logo
BEAM
Beam Therapeutics
1.3$66.88-1.0%$4.18 billion$20,000.00-4.76Earnings Announcement
Analyst Report
News Coverage
Gap Down
Iovance Biotherapeutics logo
IOVA
Iovance Biotherapeutics
1.9$26.08-1.6%$3.99 billionN/A-13.58Earnings Announcement
Analyst Revision
News Coverage
Gap Down
Allogene Therapeutics logo
ALLO
Allogene Therapeutics
1.3$27.95-0.4%$3.96 billionN/A-13.12Analyst Revision
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.8$69.93-2.7%$3.43 billionN/A-40.19Earnings Announcement
Analyst Downgrade
News Coverage
Relay Therapeutics logo
RLAY
Relay Therapeutics
1.8$27.61-2.9%$2.50 billionN/A0.00
NanoString Technologies logo
NSTG
NanoString Technologies
1.7$51.83-7.6%$2.34 billion$125.57 million-30.31Earnings Announcement
Analyst Report
News Coverage
Gap Down
Revolution Medicines logo
RVMD
Revolution Medicines
1.7$31.65-0.0%$2.32 billion$50.04 million0.00Earnings Announcement
Analyst Report
News Coverage
Gap Down
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.5$12.49-2.8%$2.22 billion$48.83 million-16.43Earnings Announcement
Vericel logo
VCEL
Vericel
1.1$47.20-6.0%$2.19 billion$117.85 million-4,720,000.00Analyst Report
Analyst Revision
Gap Down
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
0.9$48.04-6.3%$2.16 billionN/A0.00Earnings Announcement
High Trading Volume
Editas Medicine logo
EDIT
Editas Medicine
1.6$31.72-3.4%$2.15 billion$20.53 million-18.23Earnings Announcement
Analyst Report
Gap Down
bluebird bio logo
BLUE
bluebird bio
1.8$29.85-1.2%$2.01 billion$44.67 million-2.72Analyst Revision
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.8$23.25-8.5%$1.89 billionN/A-10.86Earnings Announcement
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$6.58-6.1%$1.89 billion$31.43 million-4.51
Ocugen logo
OCGN
Ocugen
1.0$8.61-15.0%$1.71 billionN/A-5.82Earnings Announcement
Analyst Report
Replimune Group logo
REPL
Replimune Group
1.5$36.05-2.9%$1.68 billionN/A-20.37
Immunovant logo
IMVT
Immunovant
1.6$15.63-1.0%$1.53 billionN/A-12.12Analyst Report
Unusual Options Activity
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.4$35.04-1.1%$1.51 billionN/A0.00Analyst Upgrade
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$10.47-1.7%$1.51 billion$102.43 million-17.45Analyst Report
Analyst Revision
Curis logo
CRIS
Curis
0.9$16.27-39.6%$1.49 billion$10 million-19.84High Trading Volume
Unusual Options Activity
News Coverage
Trading Halted
REGENXBIO logo
RGNX
REGENXBIO
1.6$34.81-2.8%$1.48 billion$35.23 million-14.04Earnings Announcement
Analyst Upgrade
AlloVir logo
ALVR
AlloVir
1.5$22.63-0.9%$1.47 billionN/A0.00Earnings Announcement
Analyst Report
Insider Selling
Analyst Revision
News Coverage
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$62.71-4.7%$1.39 billionN/A-42.37Earnings Announcement
News Coverage
Alector logo
ALEC
Alector
1.3$16.79-0.4%$1.34 billion$21.22 million-7.53
Translate Bio logo
TBIO
Translate Bio
1.6$16.73-6.7%$1.26 billion$7.80 million-15.64Analyst Report
Analyst Revision
Gap Down
Forma Therapeutics logo
FMTX
Forma Therapeutics
1.8$26.13-0.1%$1.24 billion$100.56 million0.00Upcoming Earnings
News Coverage
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$13.83-0.6%$1.16 billionN/A-2.99Analyst Report
Cortexyme logo
CRTX
Cortexyme
1.3$36.57-0.6%$1.08 billionN/A-15.24Earnings Announcement
Insider Selling
News Coverage
Gap Down
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$13.85-1.7%$1.05 billion$356.07 million6.79Earnings Announcement
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$27.85-5.9%$1.01 billionN/A-4.60Earnings Announcement
Analyst Revision
News Coverage
Scholar Rock logo
SRRK
Scholar Rock
1.5$28.60-4.3%$983.64 million$20.49 million-11.87Upcoming Earnings
News Coverage
Gap Down
Vaxcyte logo
PCVX
Vaxcyte
1.7$18.67-7.1%$958.80 millionN/A0.00Earnings Announcement
News Coverage
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.32-0.1%$937.02 million$42.74 million-225.78Earnings Announcement
Analyst Revision
News Coverage
Passage Bio logo
PASG
Passage Bio
1.8$16.69-2.3%$900.88 millionN/A0.00Analyst Revision
Gap Down
Mesoblast logo
MESO
Mesoblast
1.4$6.69-1.0%$867.31 million$32.16 million-7.60
This page was last updated on 5/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.